StockData

Repligen vs Twist Bioscience

RGEN and TWST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RGEN and TWST compare

Repligen is the larger company, worth 1.5 times as much as Twist Bioscience ($10.4B against $7.0B).

Twist Bioscience grew revenue faster over the last twelve months (19.2% versus 13.8% for Repligen).

Repligen keeps more of each dollar of sales as profit, with a net margin of −1.5% compared with −31.7% at Twist Bioscience.

Twist Bioscience scores higher on the StockData Score (13 against 7 for Repligen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRGENTWST
Size and price
Market cap$10.4B$7.0B
Share price$162.18$112.00
Change, 1 year6.4%317%
Change, 5 years−43.3%17.9%
Beta (5Y)1.361.75
Employees2,000979
StockData Score
Total score713 (better)
Valuation score00
Growth score34 (better)
Performance score23 (better)
Health score26 (better)
Dividend score00
Valuation
P/S12.9× (better)16.3×
P/B5.0× (better)15.8×
EV/EBITDA98.9×–
P/FCF97.1×–
FCF yield1.0% (better)−1.3%
Fair value$69.93$33.86
Margin of safety−132% (better)−231%
Growth
Revenue growth (TTM)13.8%19.2% (better)
Revenue growth, 5Y average15.0%33.1% (better)
Net income growth (TTM)−779%–
EPS growth, 5Y average−5.0%–
Profitability
Gross margin53.5% (better)52.0%
Operating margin2.3% (better)−33.6%
Net margin−1.5% (better)−31.7%
FCF margin13.2% (better)−21.6%
Return on equity−0.57% (better)−29.6%
Return on invested capital0.71% (better)−45.5%
Financial health
Debt / equity–0.00
Interest coverage0.8×–
Current ratio9.88 (better)2.67
Altman Z-score8.4115.90 (better)
Piotroski F-score7 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%122%
Held by insiders0.59%2.5%
Insider net buying, 12 months−$6.7M (better)−$148M
Superinvestors holding2–
Short interest, % of float11.1%16.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.